RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

OT: ACAD
Psychiatrists don't like to have the ratio of drug A to drug B decided by pre-packaging. They like to tweak the balance of dosing, and I think, rightly so--psych patients are so idiosyncratic.

Example: Lilly packaged Cymbalta and Zyprexa together as Symbyax, thinking this would be a good hedge against Zyprexa's patent expiration. Psychiatrists hated it---I talked to a Lilly person last year who told me their Symbyax prescriptions each month were in the dozens.

This pimavanserin news has been out since Biovail's CC, large holders could have dumped already if they wanted to. I've sent a query to someone, the answer will be informative as to just how much of a problem this is. I just don't know yet.

NeuroInvestment